
Ann M Ginsberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4454169/publications.pdf Version: 2024-02-01



ANN M CINSPERC

#	Article	IF	CITATIONS
1	Prevention of <i>M. tuberculosis</i> Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine, 2018, 379, 138-149.	13.9	532
2	Final Analysis of a Trial of M72/AS01 _E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2019, 381, 2429-2439.	13.9	350
3	Phase 2b Controlled Trial of M72/AS01 _E Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2018, 379, 1621-1634.	13.9	319
4	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 638-648.	2.5	124
5	Safety and immunogenicity of the novel tuberculosis vaccine ID93â€^+â€^GLA-SE in BCC-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respiratory Medicine,the, 2018, 6, 287-298.	5.2	122
6	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 220-231.	2.5	75
7	Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Seminars in Immunology, 2020, 50, 101431.	2.7	57
8	Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PLoS ONE, 2017, 12, e0175215.	1.1	57
9	Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis, 2015, 95, 352-357.	0.8	37
10	Designing tuberculosis vaccine efficacy trials – lessons from recent studies. Expert Review of Vaccines, 2019, 18, 423-432.	2.0	20
11	Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations. Vaccine, 2020, 38, 135-142.	1.7	20
12	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. Communications Biology, 2020, 3, 563.	2.0	14
13	Diagnostic Accuracy of Early Secretory Antigenic Target-6–Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. Clinical Infectious Diseases, 2019, 69, 1724-1730.	2.9	12
14	Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. Tuberculosis, 2013, 93, 136-142.	0.8	8
15	Tuberculosis Vaccines. , 2018, , 1095-1113.e9.		3